

Journal of
Medicinal Chemistry

J. Med. Chem., 1996, 39(16), 3039-3043, DOI:[10.1021/jm9603274](https://doi.org/10.1021/jm9603274)

Terms & Conditions

Electronic Supporting Information files are available without a subscription to ACS Web Editions. The American Chemical Society holds a copyright ownership interest in any copyrightable Supporting Information. Files available from the ACS website may be downloaded for personal use only. Users are not otherwise permitted to reproduce, republish, redistribute, or sell any Supporting Information from the ACS website, either in whole or in part, in either machine-readable form or any other form without permission from the American Chemical Society. For permission to reproduce, republish and redistribute this material, requesters must process their own requests via the RightsLink permission system. Information about how to use the RightsLink permission system can be found at <http://pubs.acs.org/page/copyright/permissions.html>



ACS Publications
MOST TRUSTED. MOST CITED. MOST READ.

Copyright © 1996 American Chemical Society

JM9603274

M - 1

Enzyme Assays

The rate of increase in absorbance at 405 nM due to hydrolysis of synthetic chromogenic peptide substrates (from American Diagnostica; 5-100 μ M H-D-HHT-L-Ala-L-Arg-pNA for thrombin, 0.1-3 mM Cbo-Gly-D-Ala-Arg-pNA for trypsin, 20-500 μ M H-D-Nle-HHT-Lys-pNA for plasmin, 30-700 μ M H-D-Lys-(ϵ -Cbo)-Pro-Arg-pNA for protein Ca, 30-1000 μ M CH₃SO₂-D-CHT-Gly-Arg-pNA for tPA, 70-3000 μ M H-D-Nle-HHT-Lys-pNA for streptokinase) was measured in the presence and absence of inhibitors (I) with a microplate reader at 37 °C. The enzyme reaction is started by the addition of enzyme (0.9 nM human α -thrombin, 3.2 U/mL bovine trypsin, 1.4 μ g/mL (0.049 CU) human plasmin, 3.63 mM activated human protein C, 724 IU/mL Bowes melanoma 2-chain tPA activity standard, 15.1 IU/mL streptokinase in the presence of 6.5 μ g/mL Lys-type human plasminogen). Data were collected over a period of 30 min and the initial rate of substrate hydrolysis [V_0 (mOD/min)] was calculated. Following Michaelis-Menten kinetics, the affinity of the enzyme for the substrate, in the absence of the inhibitor (K_m) and in the presence of an inhibitor (K_p), is determined to be the negative inverse x-intercept of Lineweaver-Burk plots. The K_i values were calculated by using the equation: $K_i = (K_m[I]) / (K_p - K_m)$.

Trypsin-catalyzed hydrolysis rates were measured using the same type of procedure. Bovine type-1 trypsin (Sigma) and Spectrozyme[®] TRY (Cbo-Gly-D-Ala-Arg-pNA•AcOH; American Diagnostica) replaced their thrombin equivalents in a concentration range of 3.2 U/mL trypsin and 0.1-0.3 mM Spectrozyme[®].

Enzyme Inhibition: K_i Values^a

cmpd	trypsin	plasmin	tPA	prot. Ca	SK
2	3.1 ± 1.7 (3)	2,200 ± 600 (5)	620 ± 32 (6)	3,600 ± 1,500 (5)	1,200 ± 600 (6)
efegatran	3.9 ± 1.3 (6)	330 ± 80 (5)	1,300 ± 700 (8)	720 ± 200 (5)	1,700 ± 200 (6)
argatroban	2,900 ± 1200 (6)	400 ± 58 μ M (3)	370 ± 140 μ M (3)	no inhibition	no inhibition

a. K_i values, mean, and standard error are given in nM, except where noted otherwise; the number of experiments (N) is given in parentheses. Abbreviations: tPA = tissue-type plasminogen activator, Prot. Ca = activated protein C, and SK = streptokinase.

Human Platelet Aggregation Methods

Platelet concentrate (Biological Specialties, Inc) was centrifuged at 1000 rpm (Sorvall RT 6000B) at 25 °C for 10 min. The resultant platelet-rich plasma (PRP) was gel filtered (Sephacrose 2B, Pharmacia) in Tyrode's buffer (140 mM NaCl, 2.7 mM KCl, 12 mM NaHCO₃, 0.76 mM Na₂HPO₄, 5.5 mM glucose, 5.0mM Hepes, and 2 mg/mL BSA; pH = 7.4). The gel-filtered platelets were diluted with Tyrode's buffer, compound solution in buffer, and 2 mM CaCl₂ to achieve 100,000 pl/ μ L final assay concentration on the 96-well assay plates. Platelet aggregation was initiated by the addition of a concentration of human α -thrombin (American Diagnostica) shown in preliminary experiments (on the day of the test) to achieve 80% aggregation (0.005-0.25 NIH U/mL). The assay plate was stirred and intermittently placed in a microplate reader (Molecular Devices) to read optical density (650 nm; Δ SOFT) at 0 and 7 min after the addition of thrombin. Aggregation was calculated to be the decrease in optical density between the time-zero and 7-min measurements. The assay was determined to be valid when the percent aggregation of the control was >75%. Each concentration of inhibitor, vehicles, and buffer controls were run in duplicate.